Sort   by:  
 Page size 
ProteomicsPhosphoproteomics analysis of CHK1 inhibitor treatment
Inhibitors of checkpoint kinase 1 (CHK1),a central component of DNA damage and cell cycle checkpoint response, represent a promising new cancer therapy, but the global cellular functionsthey regulate through phosphorylationare poorly understood. To elucidate the CHK1-regulated phosphorylation networ...
ORGANISM(S): Homo sapiens (Human) 
2020-04-23 | PXD015125 | Pride
Chk1 inhibitor Silac Phosphoprotomics 
TranscriptomicsTranscription profiling of human diploid and tetraploid HCT116 cells treated with cisplatin and/or a Chk1 inhibitor to investigate resistance to genotoxic stress
Tetraploid cells are more resistant against genotoxic stress (irradiation, platinum compounds, topoisomerase inhibitors) than their diploid precursors. Here, we studied the effect of cisplatin and/or Chk1 inhibition on the transcriptome of diploid and tetraploid HCT116 cells
ORGANISM(S): Homo sapiens 
2008-06-09 | E-TABM-172 | biostudies-arrayexpress
GenomicsCHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress
CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress
PRJNA664943 | ENA
ProteomicsIdentification of post translational modifications of human Topoiosmerase 1 in the presence of camptothecin and CHK1 inhibitor SCH900776.
Topisomerase 1 (TOP1), an essential enzyme in humans, plays a critical role in relaxation of DNA supercoils during replication and transcription. The TOP1 reaction cycle involves an obligate TOP1-DNA covalent complex intermediate (TOP1cc), which is stabilized by TOP1 poisons like camptothecin. While...
ORGANISM(S): Homo sapiens (Human) 
2026-03-16 | PXD055870 | Pride
Topoisomerase 1 Mk-8776 Chk1 Sch900776 Camptothecin 
ProteomicsThe phosphoproteomics study of Chk1 and ATR inhibitors regulation on cells
Ataxia Telangiectasia and Rad3-related (ATR) and Checkpoint Kinase 1 (Chk1) are crucial kinases in the DNA Damage Response (DDR) pathway. While the roles of ATR and Chk1 within the DDR are well-established, their roles in mitosis are not fully understood. Here, we describe that the ATR-Chk1 pathway ...
ORGANISM(S): Homo sapiens (Human) 
2025-06-23 | PXD058541 | Pride
Phosphoproteomics Cdk1 Inhibitor Chk1 
TranscriptomicsCastalin induces ROS production, leading to DNA damage and increasing the activity of CHK1 inhibitor in cancer cell lines
Background: cancer therapy is one of the challenging arguments in constant development. One of the principal problems connected with the tumor therapy arise form the potential side effects connected with the classical chemotherapeutic treatment but also with the molecular target therapy. The identif...
ORGANISM(S): Homo sapiens 
2025-09-04 | E-MTAB-15334 | biostudies-arrayexpress
TranscriptomicsExpression data of CHK1 shRNA knockdown and control shRNA in U2OS cells
Homologous recombination-mediated DNA repair deficiency (HRD) predisposes to cancer development, but also provides therapeutic opportunities. Here, we identified an HRD gene signature that robustly predicted HRD status. Unexpectedly, concurrent loss of PTEN in BRCA1-deficient cells might extensively...
ORGANISM(S): Homo sapiens 
2014-01-24 | E-GEOD-54267 | biostudies-arrayexpress
TranscriptomicsCHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress
While effective anti-cancer drugs targeting the CHK1 kinase are advancing in the clinic, drug resistance is rapidly emerging. Here, we demonstrate that CRISPR-mediated knockout of the little-known gene FAM122A confers cellular resistance to CHK1 inhibitors and cross-resistance to ATR inhibitors. Kno...
ORGANISM(S): Homo sapiens 
2021-01-01 | GSE158338 | GEO
GenomicsThe selective RRM2 inhibitor TAS1553 is synergistic with multiple CHK1 inhibitors in neuroblastoma
The selective RRM2 inhibitor TAS1553 is synergistic with multiple CHK1 inhibitors in neuroblastoma
PRJNA1170975 | ENA
ProteomicsCalreticulin mutated hematopoietic cells are vulnerable to ATR-CHK1 pathway inhibition
Disease frameshift mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF). To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we aimed to search for small molecule drugs th...
ORGANISM(S): Mus musculus (Mouse) 
2021-09-07 | PXD026803 | Pride
Mouse Mpn Calreticulin mutant Myeloproliferative neoplasms Atr-chk1 pathway 
Sort   by:  
 Page size